Please assess the completion status of the following clinical trial:

Trial Title: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~General Inclusion Criteria~1. Subject ≥ 18 years old.~2. Subject experiencing clinical symptoms consistent with AMI of \>30 min. in duration.~3. ST elevation ≥1 mm in ≥2 contiguous leads or new left bundle branch block, or true posterior MI with ST depression of ≥1 mm in ≥2 contiguous anterior leads.~4. Symptom duration is \<12 hours prior to signing informed consent.~5. Subject should be in catheterization laboratory and procedure started within 2 hours of consent.~6. Patient provides written informed consent.~7. Patient agrees to all required follow-up procedures and visits.~Angiographic Inclusion Criteria~1. Based on coronary anatomy, PCI is indicated for the culprit lesion with anticipated use of stenting.~2. The vessel diameter is either known or expected to be 2.5-4.0mm, without excessive tortuosity or diffuse distal disease.~3. Lesion length ≥12mm and ≤ 23mm~   -~Exclusion Criteria:~General Exclusion Criteria~1. Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints.~2. A previous coronary interventional procedure of any kind within 30 days prior to the procedure.~3. Female patients of childbearing potential known to be pregnant.~4. Patients undergoing cardiopulmonary resuscitation.~5. Cardiogenic shock (SBP \<80 mmHg for \>30 minutes, or requiring IV pressors or emergency IABP for hypotension).~6. The subject requires multivessel PCI at time of index procedure or any staged procedure of the target vessel within 9 months or any non-target vessel within 30 days post-procedure.~7. The target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.). Thrombus aspiration may be used per operator discretion.~8. Attempted thrombolysis.~9. Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial.~10. Concurrent medical condition with a life expectancy of less than 12 months.~11. Known left ventricular ejection fraction (LVEF) \< 25% at the most recent evaluation (prior to the index hospitalization).~12. History of cerebrovascular accident or transient ischemic attack in the last 6 months.~13. Active peptic ulcer or active gastrointestinal (GI) bleeding.~14. History of bleeding diathesis or coagulopathy or inability to accept blood transfusions.~15. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, or sensitivity to contrast media, which cannot be adequately pre-medicated.~16. Known serum creatinine level \> 2.5 mg/dl, eGFR \<30, or hemodialysis dependent.~Angiographic Exclusion Criteria~1. Unprotected left main coronary artery disease (obstruction greater than 60% in the left main coronary artery that is not protected by at least one non-obstructed bypass graft to the left anterior descending (LAD) or left circumflex (LCX) artery or a branch thereof).~2. Multi-vessel intervention required during the index procedure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STENTYS self-apposing stent (Type: EXPERIMENTAL): Intervention to treat STEMI with the STENTYS self-apposing stent
- VISION balloon-expandable stent (Type: ACTIVE_COMPARATOR): STEMI treatment with a VISION balloon-expandable stent

Based on this trial design, predict the completion outcome and termination type (if applicable).